Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Rocket Pharmaceuticals (RCKT) Current Deferred Revenue: 2018-2022

Historic Current Deferred Revenue for Rocket Pharmaceuticals (RCKT) over the last 5 years, with Dec 2022 value amounting to $597,000.

  • Rocket Pharmaceuticals' Current Deferred Revenue changed negligibly% to $597,000 in Q2 2023 from the same period last year, while for Jun 2023 it was $597,000, marking a year-over-year negligible change of negligibly%. This contributed to the annual value of $597,000 for FY2022, which is negligibly% changed negligibly from last year.
  • According to the latest figures from FY2022, Rocket Pharmaceuticals' Current Deferred Revenue is $597,000, which was down 0.00% from $597,000 recorded in FY2021.
  • Rocket Pharmaceuticals' 5-year Current Deferred Revenue high stood at $597,000 for FY2021, and its period low was $534,000 during FY2018.
  • In the last 3 years, Rocket Pharmaceuticals' Current Deferred Revenue had a median value of $597,000 in 2022 and averaged $594,667.
  • Data for Rocket Pharmaceuticals' Current Deferred Revenue shows a peak YoY grew of 5.24% (in 2019) over the last 5 years.
  • Yearly analysis of 5 years shows Rocket Pharmaceuticals' Current Deferred Revenue stood at $534,000 in 2018, then grew by 5.24% to $562,000 in 2019, then grew by 4.98% to $590,000 in 2020, then grew by 1.19% to $597,000 in 2021, then remained steady at $597,000 in 2022.